drugset / Trial / NCT00685399
Safety and Efficacy of AIN457 in Noninfectious Uveitis
RandomizedParallel-groupDouble-blindTreatment
Summary
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
Timeline
- Start
- 2008-06
- Primary completion
- 2013-09
- Completion
- 2013-09
Publications
- Results Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL; AIN457A2208 Study Group. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015 May;122(5):939-48. doi: 10.1016/j.ophtha.2014.12.033. Epub 2015 Jan 29.
- Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH; Psoriasis Study Group; Durez P, Tak PP, Gomez-Reino JJ; Rheumatoid Arthritis Study Group; Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD; Uveitis Study Group; Rose K, Haider A, Di Padova F. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010 Oct 6;2(52):52ra72. doi: 10.1126/scitranslmed.3001107.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secukinumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Secukinumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Secukinumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Secukinumab | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | Secukinumab | Monoclonal antibody | 300 mg | Intravenous |